MedPath

Sofosbuvir and velpatasvir

Generic Name
Sofosbuvir and velpatasvir
Indication

1.用于治疗基因1～6型、混合型及未知型慢性丙型肝炎病毒(HCV) 的成人感染患者。

2.美国FDA批准用于治疗6岁及以上或体重超过17千克的6种基因型（GT-1,-2,-3,-4,-5,-6）的HCV儿童感染者（无肝硬化或轻度肝硬化）。

Clinical Trials
Related News

Fecal Microbiota Therapy Shows 95% Success Rate in Preventing Recurrent C. difficile Infection

• Phase 3b trial demonstrates colonoscopic administration of Rebyota (fecal microbiota live-jslm) achieves 95.1% treatment success in preventing recurrent C. difficile infection with minimal adverse events. • The CDI-SCOPE study spanning 12 US sites received overwhelmingly positive physician feedback, with over 90% reporting satisfaction with both the procedure and patient outcomes. • This microbiota-based therapy represents a significant advancement over traditional fecal transplant approaches by providing a more structured and accessible restoration technique for gut microbiome.

Atea's Phase 2 Hepatitis C Regimen Shows High Efficacy, Phase 3 Planned for 2025

• Atea Pharmaceuticals' Phase 2 study of bemnifosbuvir and ruzasvir for hepatitis C met its primary endpoint, demonstrating a 98% SVR12 rate in treatment-adherent patients. • The combination regimen was generally safe and well-tolerated, with no drug-related serious adverse events or treatment discontinuations reported during the trial. • Atea plans to initiate a global Phase 3 program in early 2025, aiming to simplify the regimen to a two-pill, fixed-dose combination for enhanced patient convenience.

Biopharma Sector Shows Recovery: Bristol-Myers Squibb and Gilead Lead Market Gains

• The biopharmaceutical sector is showing signs of recovery, with a 2% rise in combined market capitalization among the top 20 global companies. • Bristol-Myers Squibb led the recovery with a 24.6% increase in market capitalization, driven by the FDA approval of Cobenfy for schizophrenia. • Gilead Sciences experienced a 22.1% rise, spurred by FDA approvals for Livdelzi in primary biliary cholangitis and Trodelvy in HR-/HER2- breast cancer. • Novo Nordisk and Eli Lilly faced setbacks, with Novo Nordisk seeing an 18.2% drop after the FDA rejected its weekly insulin icodec application.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy